Cardiff Oncology Inc (FRA:XE7C)
€ 2.975 -0.145 (-4.65%) Market Cap: 142.29 Mil Enterprise Value: 82.00 Mil PE Ratio: 0 PB Ratio: 2.53 GF Score: 50/100

Cardiff Oncology Inc at JMP Securities Hematology Oncology Summit (Virtual) Transcript

Dec 07, 2022 / 08:00PM GMT
Release Date Price: €1.37 (-6.25%)
Silvan Türkcan
JMP Securities LLC - Analyst

Welcome to Day 2 of our annual JMP Hematology and Oncology Conference. My name is Silvan Türkcan and I'm Senior Analyst covering precision medicines here at JMP Securities. It's my pleasure to host Mark Erlander, Chief Executive Officer of Cardiff Oncology. Thank you so much for joining us today.

Mark Erlander
Cardiff Oncology Inc. - CEO

Well, thank you, Silvan. I really appreciate the invite and the opportunity to tell everybody a little bit about what we're doing at Cardiff Oncology.

Silvan Türkcan
JMP Securities LLC - Analyst

True, yes. And obviously, it's a very important day for KRAS today, and you're forging ahead with onvansertib development in RAS-mutated tumors. So looking forward to your presentation.

Mark Erlander
Cardiff Oncology Inc. - CEO

Okay. All right. Well, let me get started then. What is the -- why would you want to invest in Cardiff Oncology? What's the what, where, and why? Really onvansertib, we've

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot